Abemaciclib
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Biliary Tract Carcinoma
Conditions
Biliary Tract Carcinoma
Trial Timeline
Sep 24, 2021 → Aug 15, 2023
NCT ID
NCT04003896About Abemaciclib
Abemaciclib is a phase 2 stage product being developed by Eli Lilly for Biliary Tract Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT04003896. Target conditions include Biliary Tract Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02792725 | Pre-clinical | Completed |
| NCT03763604 | Pre-clinical | Completed |
| NCT06025747 | Phase 1 | Recruiting |
| NCT06678269 | Phase 1 | Recruiting |
| NCT04003896 | Phase 2 | Terminated |
| NCT04408924 | Phase 2 | Completed |
| NCT04681768 | Pre-clinical | Completed |
| NCT03891784 | Phase 2 | Active |
| NCT03837821 | Phase 1 | Active |
| NCT03339843 | Phase 2 | Completed |
| NCT03703466 | Phase 2 | Completed |
| NCT03310879 | Phase 2 | Recruiting |
| NCT02919696 | Phase 1 | Completed |
| NCT03130439 | Phase 2 | Terminated |
| NCT02981940 | Phase 2 | Active |
| NCT02846987 | Phase 2 | Active |
| NCT02482935 | Phase 1 | Completed |
| NCT02308020 | Phase 2 | Completed |
| NCT02387814 | Phase 1 | Completed |
| NCT02102490 | Phase 2 | Completed |
Competing Products
20 competing products in Biliary Tract Carcinoma